BioCentury
ARTICLE | Financial News

Roivant’s urology subsidiary files for $150M IPO

July 20, 2018 4:56 PM UTC

Urovant Sciences Ltd. (London, U.K) proposed on July 13 to raise up to $150 million in an IPO on NASDAQ underwritten by J.P. Morgan, Jefferies and Cowen. The urology play is a wholly owned subsidiary of Roivant Sciences GmbH (Basel, Switzerland), which will be Urovant's controlling shareholder following the offering...